Ex vivo cell-based assay for assessment of response to TNF inhibitors in patients with rheumatic diseases
Authors' conclusion
This functional assay could assist in predicting the odds for response to TNFi therapy, indicating whether a given patient is likely to respond to a specific TNFi.
Study context
- Population
- Patients with rheumatic diseases receiving TNF inhibitors (TNFis)
- Participants
- 82 vs 54
- Comparison
- Ex vivo PBMC IL-17A expression assay with four TNFis vs medium (control), correlated with clinical response
- Retrospectiven = 82
- Prospectiven = 54
- Outcome
- Accuracy of the ex vivo IL-17A assay in distinguishing responders from non-responders to TNFis
Methodological detailsex vivo cell-based assay, retrospective and prospective cohorts, ROC analysis
- Ex vivo cell-based assay
- Retrospective and prospective cohorts
- ROC analysis
Performance
As reported in the abstract
Accuracy of assay for predicting therapeutic response to TNFis
| Test or model | Accuracy |
|---|---|
| Retrospective | 89.5% |
| Prospective | 79% |
Accuracy
Retrospective89.5%
Prospective79%
Original publication
Ex vivo cell-based assay for assessment of response to TNF inhibitors in patients with rheumatic diseases. Rheumatology (Oxford). Published 25 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →